Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

Similar articles for PubMed (Select 23499334)

1.

Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study.

Seet RC, Rabinstein AA, Christianson TJ, Petty GW, Brown RD Jr.

J Stroke Cerebrovasc Dis. 2013 May;22(4):561-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.019. Epub 2013 Mar 15.

2.

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.

Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7.

3.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

5.

Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB.

J Am Coll Cardiol. 2014 May 27;63(20):2141-7. doi: 10.1016/j.jacc.2014.02.549. Epub 2014 Mar 19.

PMID:
24657685
6.

Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.

Lip GY, Lane DA, Buller H, Apostolakis S.

Chest. 2013 Dec;144(6):1839-47. doi: 10.1378/chest.13-1635.

PMID:
24009027
7.

Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.

Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.

Am J Geriatr Pharmacother. 2009 Jun;7(3):159-66. doi: 10.1016/j.amjopharm.2009.06.002.

PMID:
19616184
8.

Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.

Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GY.

Chest. 2013 Jan;143(1):179-84.

PMID:
22722228
9.

The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.

Barnes GD, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D, Krol GD, Froehlich JB, Kaatz S.

Thromb Res. 2014 Aug;134(2):294-9. doi: 10.1016/j.thromres.2014.05.034. Epub 2014 Jun 2.

PMID:
24929840
10.

Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation.

Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY.

Chest. 2011 Oct;140(4):918-24. doi: 10.1378/chest.10-3024. Epub 2011 Apr 21. Erratum in: Chest. 2013 Aug;144(2):721.

11.

Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).

Poli D, Antonucci E, Testa S, Ageno W, Palareti G; FCSA (Italian Federation of Anticoagulation Clinics).

Thromb Res. 2013 Jan;131(1):12-6. doi: 10.1016/j.thromres.2012.10.009. Epub 2012 Nov 8.

PMID:
23141847
13.

The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.

Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN.

J Cardiovasc Electrophysiol. 2010 May;21(5):501-7. doi: 10.1111/j.1540-8167.2009.01661.x. Epub 2009 Dec 15.

PMID:
20021521
14.

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.

Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH.

Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum in: Lancet. 2013 Jan 19;381(9862):204.

PMID:
23036896
15.

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation.

Marcucci M, Nobili A, Tettamanti M, Iorio A, Pasina L, Djade CD, Franchi C, Marengoni A, Salerno F, Corrao S, Violi F, Mannucci PM; REPOSI Investigators.

Eur J Intern Med. 2013 Dec;24(8):800-6. doi: 10.1016/j.ejim.2013.08.697. Epub 2013 Sep 12.

PMID:
24035703
16.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
17.

Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?

Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb F, Valdés M, Lip GY.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10.

18.

Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.

Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L.

Circulation. 2014 Mar 18;129(11):1196-203. doi: 10.1161/CIRCULATIONAHA.113.004777. Epub 2014 Jan 22.

19.

All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.

Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI.

J Manag Care Pharm. 2011 Nov;17(9):672-84.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk